[Asia Economy Reporter Hyunseok Yoo] Duchem Bio announced on the 15th that it has signed a business agreement with the Uzbekistan government regarding the development, production, and consulting of next-generation disease diagnostic and therapeutic radiopharmaceuticals based on manufacturing technology.
On the 3rd, the two parties held a business agreement ceremony at Duchem Bio headquarters, attended by Duchem Bio CEO Jongwoo Kim and Sardor Kariyev, Director of the Uzbekistan Pharmaceutical Agency and First Deputy Minister of Health. The Uzbekistan government signed a Memorandum of Understanding (MOU) for mutual cooperation through this strategic business partnership. Through this, Duchem Bio and Uzbekistan agreed to proceed with medical cooperation concerning the development and technology transfer of radiopharmaceuticals locally in Uzbekistan.
Deputy Minister Kariyev stated, “President Shavkat Mirziyoyev has a special interest in improving the healthcare system and public welfare in Uzbekistan. Through this deputy minister’s visit to Korea, he instructed us to make every effort to introduce advanced technologies related to next-generation cancer diagnosis and treatment, including Korea’s medical system.” He added, “He recognized the importance of radiopharmaceutical diagnostic technology and ordered the active adoption of Korea’s radiopharmaceutical manufacturing technology and know-how.”
Following the agreement ceremony, Deputy Minister Kariyev inspected Duchem Bio’s radiopharmaceutical manufacturing center located within Sinchon Severance Hospital. He said, “Uzbekistan has one radiopharmaceutical manufacturing facility, but unfortunately, it is not properly operated due to a lack of technology.” He added, “I hope that through this business agreement, Korea’s advanced radiopharmaceuticals and manufacturing technology will be introduced to Uzbekistan via Duchem Bio, and an advanced medical system will be integrated.”
Duchem Bio CEO Jongwoo Kim said, “Taking this business agreement as an opportunity, we will spare no effort in providing maximum human and technical support for the development of Uzbekistan’s radiopharmaceutical industry.” He continued, “Radiopharmaceuticals show excellent efficacy not only in cancer diagnosis but also in diagnosing brain nerve-related diseases such as Alzheimer’s dementia and Parkinson’s disease, as well as various cancers.” He added, “We will strive to apply the five related radiopharmaceuticals and diagnostic technologies currently held by Duchem Bio?Vizamil (Alzheimer’s dementia), FP-CIT (Parkinson’s disease), Dopacheck (brain tumor), FES (breast cancer), and PSMA (prostate cancer)?to Uzbekistan.”
Sardor Kariyev, Deputy Minister of Uzbekistan, representing the ‘Pharmaceutical Industry Development Agency’ under the Uzbekistan Ministry of Health, arrived in Korea on the 31st of last month. Prior to the visit of Uzbekistan President Shavkat Mirziyoyev to Korea scheduled within this year, he held consultations with major institutions in Korea, including medical institutions, and departed on the 4th.
After returning to Uzbekistan, Deputy Minister Kariyev plans to report directly to President Mirziyoyev on the MOU with Duchem Bio and other major business agreements made during his visit to Korea. Duchem Bio and the Uzbekistan side will discuss the specific details of the cooperation relationship and plan to sign an additional MOA (Memorandum of Agreement) soon.
Duchem Bio is a company focused on diagnostics and treatment in the markets of intractable cancers and brain nerve diseases, concentrating on new drug development based on open innovation. Through collaboration with global companies, it is striving to serve as a gateway to the Asian market. Duchem Bio was the first in Korea to successfully launch radiopharmaceuticals for diagnosing Alzheimer’s dementia and Parkinson’s disease consecutively. Both products have maintained the number one market share in Korea.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
